



INVITED SPEAKER PRESENTATION

Open Access

PReS13-SPK-1137: New developments in our care & understanding of JIA

MW Beresford

From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013

Published: 5 December 2013

Despite significant advances in our care and understanding of patients with Juvenile Idiopathic Arthritis (JIA), many continue to have severe, debilitating disease. A holistic multi-disciplinary approach to the care of children and their families is critical to maximise the child's physical and psychosocial development. Landmark clinical trials including more recently those of a range of biologics have significantly improved outcomes. These include trials of tocilizumab, canakinumab, and other ongoing trials that are the result of important international collaborative efforts. However predicting which children will respond in a timely manner remains an evolving art as children may be exposed to potentially toxic agents whilst finding the most suited for them. Long-term safety, as well as efficacy, is critically important.

Knowledge translation that arises in the day to day care of children into driving forward ever greater understanding of the biological basis that underpins JIA and its sub-types is ever more crucial. Similarly, our understanding of the underlying biological processes and our ability to manipulate the immune pathways with ever more accuracy offer enormous clinical opportunities, yet also challenges. Involvement of the multi-disciplinary team will ensure that best care is provided going forward.

An overview of recent advances in our care and understanding of children with JIA will focus on recent and novel treatments that are now being introduced into our care of patients.

Disclosure of interest

None declared.

doi:10.1186/1546-0096-11-S2-17
Cite this article as: Beresford: PReS13-SPK-1137: New developments in our care & understanding of JIA. *Pediatric Rheumatology* 2013 11(Suppl 2):17.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Institute of Translational Medicine, University of Liverpool, Liverpool, UK



© 2013 Beresford; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.